

OREXIGEN(TM) THERAPEUTICS COMPLETES \$30 MILLION SERIES C FINANCING

Orexigen Therapeutics

PR Newswire (11-22-2006), November 22, 2006

OREXIGEN(TM) Therapeutics, Inc., a privately held clinical-stage neuroscience company developing novel strategic approaches to the treatment of obesity, announced the completion of a \$30 million Series C private equity financing. Proceeds from the Series C financing will be used to advance OREXIGEN's clinical programs for its two lead drug candidates for the treatment of obesity and for general corporate purposes.

Existing investors participated in the financing, along with new investors MPM BioEquities and Wasatch Advisors.